Cord blood mesenchymal stem cells suppress DC-T cell proliferation via prostaglandin B2

Stem Cells and Development

Volumn 23, Issue 14, 2014, Pages 1582-1593

  Van Den Berk, Lieke C J ^a   Jansen, Bas J H ^a   Snowden, Stuart ^b   Siebers Vermeulen, Kim G C ^a   Gilissen, Christian ^c   Kögler, Gesine ^d   Figdor, Carl G ^a   Wheelock, Craig E ^b   Torensma, Ruurd ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b KAROLINSKA INSTITUTE   (Sweden)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

15 HYDROXYPROSTAGLANDIN DEHYDROGENASE; 3 [1 (4 CHLOROBENZYL) 5 FLUORO 3 METHYL 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; 6 [2 (2 CHLOROPHENYL) 4 (2 HYDROXYPHENYL) 1,3 DIOXAN 5 YL] 4 HEXENOIC ACID; 6,8 DIFLUORO 1,2,3,4 TETRAHYDRO 9 (4 METHYLSULFONYLBENZYL)CARBAZOLE 1 ACETIC ACID; ARGINASE; BETA N ACETYLHEXOSAMINIDASE A; BETA N ACETYLHEXOSAMINIDASE B; DEXAMETHASONE; GAMMA INTERFERON; GANGLIOSIDE GM2; GANGLIOSIDE GM2 ACTIVATOR PROTEIN; GANGLIOSIDE GM3; HLA G ANTIGEN; HLA G1 ANTIGEN; HLA G3 ANTIGEN; INDOLEAMINE 2,3 DIOXYGENASE; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; NITRIC OXIDE SYNTHASE; PROSTAGLANDIN B2; SERATRODAST; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; HLA ANTIGEN; PROSTAGLANDIN B;

ARTICLE; CELL CONTACT; COCULTURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; LIPID ANALYSIS; LYMPHOCYTE PROLIFERATION; MESENCHYMAL STEM CELL; MIXED CELL CULTURE; MIXED LYMPHOCYTE REACTION; PERIPHERAL BLOOD MONONUCLEAR CELL; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; RNA ISOLATION; T LYMPHOCYTE; TH1 TH2 BALANCE; UMBILICAL CORD BLOOD; UPREGULATION; CELL PROLIFERATION; FETUS BLOOD; GENETICS; IMMUNOLOGY; MESENCHYMAL STROMA CELL; METABOLISM; PATHOLOGY;

CELL PROLIFERATION; COCULTURE TECHNIQUES; DENDRITIC CELLS; FETAL BLOOD; HLA ANTIGENS; HUMANS; IMMUNOSUPPRESSION; MESENCHYMAL STROMAL CELLS; PROSTAGLANDINS B; T-LYMPHOCYTES;

EID: 84904104645     PISSN: 15473287     EISSN: 15578534     Source Type: Journal    
DOI: 10.1089/scd.2013.0433     Document Type: Article

References (69)

1. Erices A, P Conget and JJ Minguell. (2000). Mesenchymal progenitor cells in human umbilical cord blood. Br J Haematol 109:235-242.
2. Lee OK, TK Kuo, WM Chen, KD Lee, SL Hsieh and TH Chen. (2004). Isolation of multipotent mesenchymal stem cells from umbilical cord blood. Blood 103:1669-1675.
3. Bieback K, S Kern, H Kluter and H Eichler. (2004). Critical parameters for the isolation of mesenchymal stem cells from umbilical cord blood. Stem Cells 22:625-634.
4. Kögler G, S Sensken, JA Airey, T Trapp, M Muschen, N Feldhahn, S Liedtke, RV Sorg, J Fischer, et al. (2004). A new human somatic stem cell from placental cord blood with intrinsic pluripotent differentiation potential. J Exp Med 200:123-135.
5. Ghodsizad A, M Niehaus, G Kögler, U Martin, P Wernet, C Bara, N Khaladj, A Loos, M Makoui, et al. (2009). Transplanted human cord blood-derived unrestricted somatic stem cells improve left-ventricular function and prevent left-ventricular dilation and scar formation after acute myocardial infarction. Heart 95:27-35.
6. Liedtke S, EM Freytag, J Bosch, AP Houben, TF Radke, R Deenen, K Köhrer and G Kögler. (2013). Neonatal mesenchymal- like cells adapt to surrounding cells. Stem Cell Research 11:634-646.
7. Wernet P, J Fischer, A Caplan, E Zanjani, H Müller, A Knipper and G Kögler. (2004). Isolation of non-hematopoietic stem cells from umbilical cord blood. Biol Blood Marrow Transplant 10:738-739.
8. Kögler G, TF Radke, A Lefort, S Sensken, J Fischer, RV Sorg and P Wernet. (2005). Cytokine production and hematopoiesis supporting activity of cord blood-derived unrestricted somatic stem cells. Exp Hematol 33:573-583.
9. Jansen BJ, C Gilissen, H Roelofs, A Schaap-Oziemlak, JA Veltman, RA Raymakers, JH Jansen, G Kogler, CG Figdor, R Torensma and GJ Adema. (2010). Functional differences between mesenchymal stem cell populations are reflected by their transcriptome. Stem Cells Dev 19:481-490.
10. Bartholomew A, C Sturgeon, M Siatskas, K Ferrer, K Mc- Intosh, S Patil, W Hardy, S Devine, D Ucker, et al. (2002). Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol 30:42-48.
11. Di Nicola M, C Carlo-Stella, M Magni, M Milanesi, PD Longoni, P Matteucci, S Grisanti and AM Gianni. (2002). Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 99:3838-3843.
12. Krampera M, S Glennie, J Dyson, D Scott, R Laylor, E Simpson and F Dazzi. (2003). Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigenspecific T cells to their cognate peptide. Blood 101:3722-3729.
13. Tse WT, JD Pendleton, WM Beyer, MC Egalka and EC Guinan. (2003). Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation. Transplantation 75:389-397.
14. van den Berk LC, CG Figdor and R Torensma. (2008). Mesenchymal stromal cells: tissue engineers and immune response modulators. Archivum immunologiae et therapiae experimentalis 56:325-329.
15. Djouad F, P Plence, C Bony, P Tropel, F Apparailly, J Sany, D Noel and C Jorgensen. (2003). Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Blood 102:3837-3844.
16. van den Berk LC, BJH Jansen, KGC Siebers-Vermeulen, MG Netea, T Latuhinin, S Bergevoet, RA Raymakers, G Kögler, CG Figdor, GJ Adema and R Torensma. (2009). Toll-like receptor triggering in cord blood mesenchymal stem cells. J Cell Mol Med 13:3415-3426.
17. van den Berk LC, BJ Jansen, KG Siebers-Vermeulen, H Roelofs, CG Figdor, GJ Adema and R Torensma. (2010). Mesenchymal stem cells respond to TNF but do not produce TNF. J Leukoc Biol 87:283-289.
18. van den Berk LC, H Roelofs, T Huijs, KG Siebers- Vermeulen, RA Raymakers, G Kogler, CG Figdor and R Torensma. (2009). Cord blood mesenchymal stem cells propel human dendritic cells to an intermediate maturation state and boost interleukin-12 production by mature dendritic cells. Immunology 128:564-572.
19. Vianello F and F Dazzi. (2008). Mesenchymal stem cells for graft-versus-host disease: A double edged sword? Leukemia 22:463-465.
20. Salem HK and C Thiemermann. (2010). Mesenchymal stromal cells: current understanding and clinical status. Stem Cells 28:585-596.
21. Phinney DG and DJ Prockop. (2007). Concise review: mesenchymal stem/multipotent stromal cells: the state of transdifferentiation and modes of tissue repair-current views. Stem Cells 25:2896-2902.
22. Chamberlain G, J Fox, B Ashton and J Middleton. (2007). Concise review: mesenchymal stem cells: their phenotype, differentiation capacity, immunological features, and potential for homing. Stem Cells 25:2739-2749.
23. Tolar J, K Le Blanc, A Keating and BR Blazar. (2010). Concise review: hitting the right spot with mesenchymal stromal cells. Stem Cells 28:1446-1455.
24. Ringden O and A Keating. (2011). Mesenchymal stromal cells as treatment for chronic GVHD. Bone Marrow Transplant 46:163-164.
25. Kim N, KI Im, JY Lim, EJ Jeon, YS Nam, EJ Kim and SG Cho. (2013). Mesenchymal stem cells for the treatment and prevention of graft-versus-host disease: experiments and practice. Ann Hematol 92:1295-1308.
26. Kögler G, J Callejas, P Hakenberg, J Enczmann, O Adams, W Daubener, C Krempe, U Gobel, T Somville and P Wernet. (1996). Hematopoietic transplant potential of unrelated cord blood: critical issues. J Hematother 5:105-116.
27. Kluth SM, A Buchheiser, AP Houben, S Geyh, T Krenz, TF Radke, C Wiek, H Hanenberg, P Reinecke, P Wernet and G Kogler. (2010). DLK-1 as a marker to distinguish unre-stricted somatic stem cells and mesenchymal stromal cells in cord blood. Stem Cells Dev 19:1471-1483.
28. Piao YF, H Ichijo, K Miyagawa, H Ohashi, F Takaku and K Miyazono. (1990). Latent form of transforming growth factorbeta 1 acts as a potent growth inhibitor on a human erythroleukemia cell line. Biochem Biophys Res Commun 167:27-32.
29. Lundström SL, R Saluja, M Adner, JZ Haeggström, G Nilsson and CE Wheelock. (2013). Lipid mediator metabolic profiling demonstrates differences in eicosanoid patterns in two phenotypically distinct mast cell populations. J Lipid Res 54:116-126.
30. Baecher-Allan C, JA Brown, GJ Freeman and DA Hafler. (2001). CD4 + CD25high regulatory cells in human peripheral blood. J Immunol 167:1245-1253.
31. Fontenot JD, JP Rasmussen, LM Williams, JL Dooley, AG Farr and AY Rudensky. (2005). Regulatory T cell lineage specification by the forkhead transcription factor foxp3. Immunity 22:329-341.
32. Roncador G, PJ Brown, L Maestre, S Hue, JL Martinez- Torrecuadrada, KL Ling, S Pratap, C Toms, BC Fox, et al. (2005). Analysis of FOXP3 protein expression in human CD4 + CD25 + regulatory T cells at the single-cell level. Eur J Immunol 35:1681-1691.
33. Le Blanc K, I Rasmusson, B Sundberg, C Gotherstrom, M Hassan, M Uzunel and O Ringden. (2004). Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 363:1439-1441.
34. Maccario R, M Podesta, A Moretta, A Cometa, P Comoli, D Montagna, L Daudt, A Ibatici, G Piaggio, et al. (2005). Interaction of human mesenchymal stem cells with cells involved in alloantigen-specific immune response favors the differentiation of CD4+ T-cell subsets expressing a regulatory/ suppressive phenotype. Haematologica 90:516-525.
35. Prevosto C, M Zancolli, P Canevali, MR Zocchi and A Poggi. (2007). Generation of CD4 + or CD8 + regulatory T cells upon mesenchymal stem cell-lymphocyte interaction. Haematologica 92:881-888.
36. Di Ianni M, B Del Papa, M De Ioanni, L Moretti, E Bonifacio, D Cecchini, P Sportoletti, F Falzetti and A Tabilio. (2008). Mesenchymal cells recruit and regulate T regulatory cells. Exp Hematol 36:309-318.
37. Beyth S, Z Borovsky, D Mevorach, M Liebergall, Z Gazit, H Aslan, E Galun and J Rachmilewitz. (2005). Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness. Blood 105: 2214-2219.
38. Aggarwal S and MF Pittenger. (2005). Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 105:1815-1822.
39. Shiraishi H, H Yoshida, K Saeki, Y Miura, S Watanabe, T Ishizaki, M Hashimoto, G Takaesu, T Kobayashi and A Yoshimura. (2008). Prostaglandin E2 is a major soluble factor produced by stromal cells for preventing inflammatory cytokine production from dendritic cells. Int Immunol 20:1219-1229.
40. Sato K, K Ozaki, I Oh, A Meguro, K Hatanaka, T Nagai, K Muroi and K Ozawa. (2007). Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells. Blood 109:228-234.
41. Noël D, F Djouad, C Bouffi, D Mrugala and C Jorgensen. (2007). Multipotent mesenchymal stromal cells and immune tolerance. Leuk Lymphoma 48:1283-1289.
42. Meisel R, A Zibert, M Laryea, U Gobel, W Daubener and D Dilloo. (2004). Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenasemediated tryptophan degradation. Blood 103:4619-4621.
43. Rizzo R, D Campioni, M Stignani, L Melchiorri, GP Bagnara, L Bonsi, F Alviano, G Lanzoni, S Moretti, et al. (2008). A functional role for soluble HLA-G antigens in immune modulation mediated by mesenchymal stromal cells. Cytotherapy 10:364-375.
44. Nasef A, N Mathieu, A Chapel, J Frick, S Francois, C Mazurier, A Boutarfa, S Bouchet, NC Gorin, D Thierry and L Fouillard. (2007). Immunosuppressive effects of mesenchymal stem cells: involvement of HLA-G. Transplantation 84:231-237.
45. Rouas-Freiss N, RM Goncalves, C Menier, J Dausset and ED Carosella. (1997). Direct evidence to support the role of HLA-G in protecting the fetus from maternal uterine natural killer cytolysis. Proc Natl Acad Sci U S A 94:11520-11525.
46. Ishitani A and DE Geraghty. (1992). Alternative splicing of HLA-G transcripts yields proteins with primary structures resembling both class I and class II antigens. Proc Natl Acad Sci U S A 89:3947-3951.
47. Fujii T, A Ishitani and DE Geraghty. (1994). A soluble form of the HLA-G antigen is encoded by a messenger ribonucleic acid containing intron 4. J Immunol 153:5516-5524.
48. Lila N, N Rouas-Freiss, J Dausset, A Carpentier and ED Carosella. (2001). Soluble HLA-G protein secreted by allospecific CD4 + T cells suppresses the allo-proliferative response: A CD4 + T cell regulatory mechanism. Proc Natl Acad Sci U S A 98:12150-12155.
49. Le Friec G, B Laupeze, O Fardel, Y Sebti, C Pangault, V Guilloux, A Beauplet, R Fauchet and L Amiot. (2003). Soluble HLA-G inhibits human dendritic cell-triggered allogeneic T-cell proliferation without altering dendritic differentiation and maturation processes. Hum Immunol 64:752-761.
50. Bennaceur K, I Popa, J Portoukalian, O Berthier-Vergnes and J Peguet-Navarro. (2006). Melanoma-derived gangliosides impair migratory and antigen-presenting function of human epidermal Langerhans cells and induce their apoptosis. Int Immunol 18:879-886.
51. Bergelson LD, EV Dyatlovitskaya, TE Klyuchareva, EV Kryukova, AF Lemenovskaya, VA Matveeva and EV Sinitsyna. (1989). The role of glycosphingolipids in natural immunity. Gangliosides modulate the cytotoxicity of natural killer cells. Eur J Immunol 19:1979-1983.
52. Peguet-Navarro J, M Sportouch, I Popa, O Berthier, D Schmitt and J Portoukalian. (2003). Gangliosides from human melanoma tumors impair dendritic cell differentiation from monocytes and induce their apoptosis. J Immunol 170:3488-3494.
53. Palacios R and I Sugawara. (1982). Hydrocortisone abrogates proliferation of T cells in autologous mixed lymphocyte reaction by rendering the interleukin-2 Producer T cells unresponsive to interleukin-1 and unable to synthesize the T-cell growth factor. Scand J Immunol 15: 25-31.
54. Lanz TV, CA Opitz, PP Ho, A Agrawal, C Lutz, M Weller, AL Mellor, L Steinman, W Wick and M Platten. (2010). Mouse mesenchymal stem cells suppress antigen-specific TH cell immunity independent of indoleamine 2,3- dioxygenase 1 (IDO1). Stem Cells Dev 19:657-668.
55. Otani T, K Yamaguchi, E Scherl, B Du, HH Tai, M Greifer, L Petrovic, T Daikoku, SK Dey, K Subbaramaiah and AJDannenberg. (2006). Levels of NAD( + )-dependent 15- hydroxyprostaglandin dehydrogenase are reduced in inflammatory bowel disease: evidence for involvement of TNF-alpha. Am J Physiol Gastrointest Liver Physiol 290:G361-G368.
56. Yang J, CE Petersen, C-E Ha and NV Bhagavan. (2002). Structural insights into human serum albumin-mediated prostaglandin catalysis. Protein Sci 11:538-545.
57. Potian JA, H Aviv, NM Ponzio, JS Harrison and P Rameshwar. (2003). Veto-like activity of mesenchymal stem cells: functional discrimination between cellular responses to alloantigens and recall antigens. J Immunol 171:3426-3434.
58. Ghannam S, C Bouffi, F Djouad, C Jorgensen and D Noel. (2010). Immunosuppression by mesenchymal stem cells: mechanisms and clinical applications. StemCell Res Ther 1:2.
59. Robb RJ and KA Smith. (1981). Heterogeneity of human Tcell growth factor(s) due to variable glycosylation. Mol Immunol 18:1087-1094.
60. Nishihira J. (2000). Macrophage migration inhibitory factor (MIF): its essential role in the immune system and cell growth. J Interferon Cytokine Res 20:751-762.
61. Campioni D, R Rizzo, M Stignani, L Melchiorri, L Ferrari, S Moretti, A Russo, GP Bagnara, L Bonsi, et al. (2008). A decreased positivity for CD90 on human mesenchymal stromal cells (MSCs) is associated with a loss of immunosuppressive activity by MSCs. Cytometry B Clin Cytom 76:225-230.
62. Le Blanc K, I Rasmusson, C Gotherstrom, C Seidel, B Sundberg, M Sundin, K Rosendahl, C Tammik and O Ringden. (2004). Mesenchymal stem cells inhibit the expression of CD25 (interleukin-2 receptor) and CD38 on phytohaemagglutinin- activated lymphocytes. Scand J Immunol 60:307-315.
63. Ramkissoon A, AM Shapiro, MM Loniewska and PG Wells. (2013). Neurodegeneration from drugs and agingderived free radicals. In: Molecular basis of oxidative stress: chemistry, mechanisms and disease pathogene. FA Villamena, ed. John Wiley & Sons, Inc., Hoboken, New Jersey, pp 242-244.
64. Cattan N, D Mary, A Peleraux, B Mari, C Aussel and B Rossi. (2000). Prostaglandin B(2) delivers a co-stimulatory signal leading to T cell activation. Eur Cytokine Netw 11:293-299.
65. Liu F, JA Orr and JY Wu. (1994). Prostaglandin B2-induced pulmonary hypertension is mediated by TxA2/PGH2 receptor stimulation. Am J Physiol 267:L602-L608.
66. Kabashima K, T Murata, H Tanaka, T Matsuoka, D Sakata, N Yoshida, K Katagiri, T Kinashi, T Tanaka, et al. (2003). Thromboxane A2 modulates interaction of dendritic cells and T cells and regulates acquired immunity. Nat Immunol 4:694-701.
67. Sayre BL and GS Lewis. (1993). Arachidonic acid metabolism during early development of ovine embryos: A possible relationship to shedding of the zona pellucida. Prostaglandins 45:557-569.
68. Adaikan GP and SMM Karim. (1974). Effect of prostaglandins A1, A2, B1, B2, E2 and F2a on human umbilical cord vessels. Prostaglandins 8:411-416.
69. Sullivan MH, CK Roseblade, NB Rendell, GW Taylor and MG Elder. (1992). Metabolism of prostaglandins E2 and F2 alpha by human fetal membranes. Biochim Biophys Acta 1123:342-346.